CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company founded in 2005 and headquartered in San Diego, California. The company went public in 2007 and focuses on developing transformative cell and exosome-based therapeutics for treating various diseases and disorders. Capricor is primarily known for its lead candidate <b>deramiocel</b> (formerly CAP-1002), an allogeneic cardiac-derived cell therapy that has completed Phase III clinical trials for treating late-stage Duchenne muscular dystrophy (DMD). The company has submitted a Biologics License Application (BLA) to the FDA for deramiocel, with a priority review PDUFA date of August 31, 2025.